Pharma BD Deal Intelligence
BASF's $3.8B cash acquisition of AHP's Cyanamid crop-protection unit doubled its ag business overnight and grew into one of BASF's largest, most durable segments—despite an early operating loss and years of restructuring before hitting targeted synergies. AHP used the proceeds to refocus on pharma, rebranded as Wyeth, and sold to Pfizer in 2009 for roughly $68 billion.
BASF Chairman Jurgen Strube framed the deal as combining the two crop protection businesses to strengthen North/South American presence; combined 1999 sales…
BASF paid the Company $3.8 billion in cash and assumed certain debt. The Company recorded an after-tax loss on the sale of this business of $1,573.0 million or…
BASF acquired American Cyanamid's agricultural division from AHP in 2000, a divestiture that completed AHP's pharma refocus and positioned BASF as a top-three…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
American Home Products sold its Cyanamid Crop Protection agricultural business to BASF for ~$3.8B in cash, completing portfolio refocus on pharmaceuticals (later renamed Wyeth in 2002). NOT pharma — flagged borderline; included for transparency on AHP/Wyeth strategic direction during the 2000 mega-merger era.
Assessment window: 10yr post-close.
$3.6B Combined BASF+Cyanamid 1999 agrochem sales (global)
Agrochemicals (herbicides, fungicides, insecticides) are crop protection inputs — not a human disease. Cyanamid Crop Protection was the agricultural division of American Home Products, divested as AHP refocused on pharmaceuticals (later renamed Wyeth in 2002).
AHP's $3.8B sale of Cyanamid Crop Protection to BASF was a non-pharma divestiture in a six-week auction that drew Bayer, Dow Chemical and DuPont; AHP originally sought ~$3B, BASF outbid the field. Post-deal, BASF leapfrogged to the #4 global agrochem position behind Syngenta, Monsanto and Aventis, with combined annual sales of ~$3.6B versus BASF's standalone $1.9B. Cyanamid's strength in insecticides complemented BASF's herbicide/fungicide base; Merck Finck analyst Michael Butscher called the fit 'complementary'. For AHP this completed portfolio refocus on human and animal pharmaceuticals during the 2000 mega-merger era and funded the company's pharma pivot. NOTE: This is a non-pharma transaction included in the database for transparency on AHP/Wyeth strategic direction; it does not have a human-disease indication, MoA or competing therapy landscape. No competing pharma asset was bought, sold or licensed. Borderline relevance flagged in source record.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| American Home Products Corporation / BASF AG (Cyanamid agricultural divestiture) (this deal) | 2000 | $3.8B | 78 |
| American Home Products Corporation / American Cyanamid Company | 1994 | $9.7B | 83 |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital) | 2013 | $1.3B | 91 |
| Stryker Corporation / MAKO Surgical Corp. | 2013 | $1.6B | 91 |
| Quintiles Transnational Holdings Inc. / IMS Health Holdings, Inc. | 2016 | $17.6B | 91 |
| DPx Holdings B.V. (JLL Partners 51% / Royal DSM 49%) / Patheon Inc. + DSM Pharmaceutical Products | 2013 | $2.6B | 90 |
← Browse all deals · How we score deals
More: 2000 deals · Other deals